First-pass extracted concept

non-viral mRNA cancer vaccines

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

mRNA-based cancer vaccines

Evidence Snippets

This scoping review synthesizes clinical trials from 2015 to 2025 investigating non-viral messenger RNA (mRNA)-based cancer vaccines.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1gapsupports2026Source 1DOI PubMed

The review identifies delivery optimization, reporting transparency, and standardization as important gaps for future non-viral mRNA cancer vaccine research.

Claim 2trendsupports2026Source 1DOI PubMed

Across 72 early-phase trials, the reviewed non-viral mRNA cancer vaccine field shifted from ex vivo DC-based approaches dominating 2015-2020 to LNP-based in vivo delivery after 2021.

Claim 3trendsupports2026Source 1DOI PubMed

Combination immunotherapies, particularly with immune checkpoint inhibitors, increased after 2019 in the reviewed non-viral mRNA cancer vaccine field.